Email this article Opyt primeneniya kapetsitabina v neoad\"yuvantnoy khimioterapii raka molochnoy zhelezy
- Authors: Slonimskaya EM1, Tarabanovskaya NA1, Bragina OD1, Garbukov EY.1, Doroshenko AV1, Kokorina Y.L1, Zav'yalova MV1
-
Affiliations:
- Issue: Vol 14, No 4 (2012)
- Pages: 22-25
- Section: Articles
- URL: https://modernonco.orscience.ru/1815-1434/article/view/29522
- ID: 29522
Cite item
Full Text
Abstract
About the authors
E M Slonimskaya
N A Tarabanovskaya
O D Bragina
E Yu Garbukov
A V Doroshenko
Yu L Kokorina
M V Zav'yalova
References
- Тюляндин С.А., Носов Д.А., Переводчикова Н.И. Минимальные клинические рекомендации Европейского общества медицинской онкологии (ЕSМО) М.: Издательская группа РОНЦ им. Н.Н.Блохина РАМН. 2010; с. 13.
- Rastogi P, Anderson SJ et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26 (5): 778-85.
- Saeki T, Takashima S. Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine. Gan To Kagaku Ryoho 1999; 26 (4): 447-55.
- Gampenrieder SP, Bartch R et al. Capecitabine and Vinorelbine as an All-Oral Chemotherapy in Her2-Negative Locally Advanced and Metastatic Breast Cancer. Breast Care 2010; 5: 158-62.
- Seidman AD, Brufsky A et al. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to alternate single agent in metastatic breast cancer. Ann Oncology 2011; 22: 1094-101.
- Shien T, Doihara H et al. Clinical Efficacy of Capecitabine and Cyclophosphamide (XC) in Patients with Metastatic Breast Cancer. Acta Med Okayama 2011; 65 (4): 231-7.
- Amari M, Ishida T et al. Capecitabine Monotherapy is Efficient and Safe in All Line Settings in Patients with Metastatic and Advanced Breast Cancer. Jpn J Clin Oncology 2010; 40 (3): 188-93.
- Wildiers H, Neven P et al. Neoadjuvant capecitabine and docetaxel (plus trasruzumab): an effective non-antracycline-based chemotherapy regimen for patients with locally advanced breast cancer. Ann Oncology 2011; 22 (3): 588-94.
- Wardley AM. Capecitabine: Expanding Options for the Treatment of Patients with Early or Locally Advanced Breast Cancer. Oncologist 2006; 11: 20-6.
- Gunter von Minckwitz et al. Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresposive Breast Cancer: Phase III Randomized Gepar Trio Trial. JNCI 100 (8): 542-51.
- Lindman H, Kellokumpu-Lehtinen P-L, Huovinen R. Integration of capecitabine into anthracycline- and taxane-based adjuvant therapy for triple-negative early breast cancer: final subgroup analysis of the FinXX study. SABCS 2010; PD01-2.
- Steger GG, Barrios C, O'Shaughnessy J et al. Review of Capecitabine for the Treatment of Triple-Negative Early Breast Cancer. Cancer Res 2010; 70 (Suppl. 24): PD01-3.
- Mikhail SE, Sun JF, Marshall JL. Safety of capecitabine: a review. Expert Opin Drug Saf 2010; 9 (5): 831-41.
- Park YH et al. High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy. Ann Oncology 2003; 14: 1691-2.
- Слонимская Е.М., Тарабановская Н.А., Дорошенко А.В., Гарбуков Е.Ю, Кокорина Ю.Л. Кселода в неоадъювантном лечении операбельного рака молочной железы. Сибирский онкологический журнал. 2009; 1 (31): 14-8.
- Cleere DW. Triple-negative breast cancer: a clinical update. Community Oncology 2010; 5: 203-11.
- Arnedos M, Bihan C, Delaloge S, Andre F. Triple- negative breast cancer: are we making headway at least? Ther Adv Med Oncology 2012; 4 (4): 195-210.
- Gluz O, Liedtke C, Gottscchalk N et al. Triple-negative breast cancer - current status and future directions. Ann Oncology 2009; 20: 1913-27.
Supplementary files
